


BRD7-IN-1

Cat. No.:	HY-111905
CAS No.:	2448414-48-8
Molecular Formula:	C ₂₂ H ₂₈ Cl ₂ N ₄ O ₃
Molecular Weight:	467.39
Target:	Epigenetic Reader Domain
Pathway:	Epigenetics
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (213.95 mM; Need ultrasonic)					
	DMSO : 30 mg/mL (64.19 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		2.1395 mL	10.6977 mL	21.3954 mL
5 mM			0.4279 mL	2.1395 mL	4.2791 mL	
10 mM		0.2140 mL	1.0698 mL	2.1395 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (213.95 mM); Clear solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 3 mg/mL (6.42 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 3 mg/mL (6.42 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	BRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a PROTAC VZ185 (VZ185 against BRD7/9 with DC ₅₀ s of 4.5 and 1.8 nM, respectively) ^[1] .
IC₅₀ & Target	BRD7, BRD9 ^[1]

REFERENCES

[1]. Zoppi V, et al. Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degradation Probe of BRD9 and BRD7. J Med Chem. 2019 Jan 24;62

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA